Free tool
FAERS Monitor: Olumiant
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207924 or its brand name (Olumiant, Baricitinib). Reports on generic versions are filed under their own applications.
Reports
9,777
Serious
6,825
70% of reports
Hospitalization
3,177
Death reported
891
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective786
- off label use759
- covid-19458
- rheumatoid arthritis413
- pulmonary embolism309
- pneumonia285
- headache269
- herpes zoster243
- death237
- nausea237
- deep vein thrombosis215
- arthralgia191
- fatigue190
- condition aggravated189
- weight increased187
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 8 |
| 2018 | 314 |
| 2019 | 1,085 |
| 2020 | 846 |
| 2021 | 1,574 |
| 2022 | 1,436 |
| 2023 | 1,654 |
| 2024 | 1,408 |
| 2025 | 944 |
| 2026 | 502 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,382 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| herpes zosterSignal | 243 | 9.1 | 8.1 | 1,749 |
| rheumatoid arthritisSignal | 413 | 7.9 | 7.1 | 2,466 |
| deep vein thrombosisSignal | 215 | 7.1 | 6.3 | 1,128 |
| pulmonary embolismSignal | 309 | 7.0 | 6.3 | 1,590 |
| covid-19Signal | 458 | 5.6 | 5.1 | 1,748 |
| pneumonia | 285 | 1.9 | 1.7 | 121 |
| off label use | 759 | 1.9 | 1.7 | 317 |
| weight increased | 187 | 1.8 | 1.6 | 66 |
| condition aggravated | 189 | 1.3 | 1.2 | 16 |
| drug ineffective | 786 | 1.3 | 1.2 | 52 |
| arthralgia | 191 | 1.0 | 0.9 | 0 |
| headache | 269 | 0.9 | 0.8 | 2 |
| nausea | 237 | 0.6 | 0.6 | 48 |
| death | 237 | 0.6 | 0.5 | 69 |
| fatigue | 190 | 0.5 | 0.5 | 84 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.